MCARH109 is a first-in-class G protein–coupled receptor, class C, group 5, member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple ...

This was a multi-institutional phase II trial of neoadjuvant osimertinib for patients with surgically resectable stage I-IIIA (American Joint Committee on Cancer [AJCC] V7) EGFR-mutated (L858R or exon ...

Qualitative responses from individuals involved in the resource-limited pediatric oncology centers mentioned above reveal key enablers for the implementation of QI initiatives. 12 First, the alignment ...

Background: Effective treatment options remain an unmet need for patients (pts) with microsatellite stable/mismatch repair proficient (MSS/pMMR) metastatic colorectal cancer (mCRC). Combination ...

Depending upon prior treatment received, androgen receptor pathway inhibitors (ARPIs: enzalutamide, abiraterone with prednisone), poly(ADP-ribose) polymerase inhibitors (PARPi), chemotherapeutic ...

Fig 1.Management of the axilla for patients with clinical T ≤2 cm breast cancer. a Multidisciplinary discussion of adjuvant therapy options should occur prior to surgery when omitting sentinel lymph ...

The therapeutic potential of PD-1/PD-L1 inhibition has led to the development of multiple immune checkpoint inhibitors (ICIs). 1 Clinical outcomes with PD-(L)1 inhibitors have been positively ...

Our previous NECO phase II studies on high-grade osteosarcoma suggested that administering ifosfamide (IF; 16 g/m 2 [4g/m 2 once on day 1, then 2g/m 2 once on days 2-7] × six) to patients showing a ...

Treatment Patterns of Goserelin 3.6 mg Once Every 4 Weeks and 10.8 mg Once Every 12 Weeks in Women With Breast Cancer: A Real-World Analysis of Patients in the United States This is a retrospective, ...

PCS involves extensive surgical effort to achieve optimal debulking, defined as no residual tumor or minimal residual disease. This approach has been associated with improved survival rates when ...

Location of tumor; useful and clinically relevant features for tumor location are provided by MRI, such as peritoneal reflection (ie, upper limit for extraperitoneal tumors v intraperitoneal tumors) ...

ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pathology, cancer genetics, and advocacy experts to conduct an updated literature search, which included ...